To evaluate if MYD88 also plays a pathological role in myeloid neoplasia, we studied MYD88 in primary samples of patients with MDS, including MYD88 mutation analysis in bone marrow mononuclear cells and the characterization of MYD88 RNA expression in bone marrow CD34+ cells and also investigated the impact of MYD88 blockade and downstream inflammatory interleukin IL-8 [13] in primary MDS CD34+ cells cultured in vitro. The gene discussed is CD34; the disease is myelodysplastic syndrome.